Patents on Myriad Genetics Inc.’s BRACAnalysis test for determining predisposition to breast and ovarian cancer are endangered by lawsuits and expiration, but the company has been diligently developing and keeping secret the contents of a genetic database to help maintain the test’s predominant position.
Myriad Wields Proprietary Database To Protect Testing Market
Myriad president Mark Capone made it clear that the company will use its proprietary database of genetic variants on the BRCA1 and BRCA2 genes to try and fend off cheaper competition after the BRACAnalysis test’s method patents are expired, or if they are overturned in court.